Invitrogen Corp. has entered into a definitive merger agreement under which Invitrogen will acquire New Jersey-based Sentigen in a cash transaction of approximately $25.9 million for all shares currently issued and outstanding. Sentigen’s Tango Assay System and division arrested Assay Ready Cells will bolster Invitrogen’s position in assay development by providing a novel approach to screen G-protein coupled receptors (GPCR) and other key drug target classes, as well as providi...